In a groundbreaking clinical development set to reshape the landscape of pain management, a recent phase I trial has unveiled the safety profile, pharmacokinetics, and pharmacodynamics of SHR8554, a novel biased µ-opioid receptor agonist. This investigational compound stands at the forefront of opioid research, offering the tantalizing prospect of effective analgesia with potentially reduced adverse […]
